Role of novel vegfr-2 inhibitors in treating the patients with advanced gastric cancer
,1,* Mohammad amin dehghani
,2 Jeiran haghighi
,3 Fatemeh dehghani
1. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2. Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4. . Department of Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Vascular endothelial growth factor receptor 2 (vegfr2) is reportedly associated with the stimulation of angiogenesis in malignancies. the targeted vegfr2 can be crucial in treating the advanced gastric cancer. among which, ramucirumab is an anti-vegfr2 monoclonal antibody in the advanced gastric cancer. in addition, apatinib mesylate is a new inhibitor of vegfr-2 tyrosine kinase, as third-line treatment for the patients with advanced gastric cancer.
The search was performed among recently published articles in english on pubmed database and findings presented at recent meetings using keywords of advanced gastric; vegfr-2 inhibitors; ramucirumab; apatinib; treatment.
Ramucirumab alone and in combination with paclitaxel have been recognized to be effective in treating the patients with advanced or metastatic gastric or cancer after prior fluoropyrimidine- or platinum-containing therapy. there were no standard second-line regimens hitherto but the regard and rainbow trials approved the role of ramucirumab in the second-line setting. during a phase ii trial, os and pfs were increased due to apatinib in the patients with chemotherapy-refractory advanced or metastatic gastric carcinoma in comparison with control group. further, the apatinib exhibited acceptable safety, tolerability and efficacy in treating the patients with advanced metastatic gc within phase i–iii trials.
: one of the therapeutic candidates for advanced gastric cancer is vegfr-2 inhibitors whose mechanism of action provides a condition to promote knowledge of this complicated route potentially for treating advanced gastric cancer.
Advanced gastric; vegfr-2 inhibitors; ramucirumab; apatinib; treatment.